|
|
Igor S. Lukashevich
M.D., Ph.D.
|
| Academic Title:
Associate Professor |
| Primary Appointment:
Medicine |
|
ilukashevich@ihv.umaryland.edu |
| Location:
UMBI,
S513 |
| Phone:
(410) 706-1366 |
| Fax:
(410) 706-4694 |
| Lab:
(410) 706-1364 |
|
Personal History
Education
1973: M. D. in Internal Medicine, Minsk Medical Institute, Minsk, Belarus
1976: Ph. D. in Virology, Institute of Virology, Academy of Medical Science, Moscow
1987: Dr. Sci. in Virology, Institute of Virology, Academy of Medical Science, Moscow
Employment History
1994-2000: Senior Scientist, Department of Pathology, Medical School, University of Wisconsin, Madison, WI
2000-2003: Senior Scientist, Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD
2002-present: Associate Scientist (Adjunct), Southwest Foundation for Biomedical Research, San Antonio, TX
2003-2006: Assistant Professor, IHV/UMBI, Baltimore, MD
2006-present: Associate Professor, IHV/SoM, Baltimore, MD
Research Interests
My long-standing interest is molecular biology, pathogenesis, and prevention of diseases caused by Hemorrhagic Fever Viruses (HFVs). These viruses belong to four different families of RNA viruses (Arenaviridae, Bunyaviridae, Filoviridae, and Flaviviridae) but they can cause a common clinical syndrome, fever, a bleeding diathesis, and circulating shock leading to fatal outcome. During last years I am focusing mostly on pathogenic arenaviruses, Lassa and LCMV (lymphocytic choriomeningitis virus). Lassa fever (LF) is a major febrile disease responsible for 10-15% of adult febrile admissions to West African hospitals, and about 40% of nonsurgical deaths. LCMV is the worldwide distributed pathogen causing congenital infections (hydrochephalus, mental retardation, and choriomeningitis) in infants and a fatal LF-like disease in immunocompromised individuals. In addition to a public health risk, HFVs also pose a biodefense threat and many of them, including Lassa and LCMV, are category A agents (CDC).
The first priority of our research efforts is to identify viral and host genes that control virulence, innate immunity, and to elucidate how the Lassa virus escapes adaptive immune control. The second goal is to design safe and efficacious vaccine. Current vaccine studies are focusing on pre-clinical development of two promising candidates, a live attenuated reassortant vaccine (clone ML29), a recombinant Yellow Fever â?" LF vaccine, and on further development of infectious DNA vaccine technology we have recently invented.
Grants and Contracts:
NIH/NIAID: 7R01AI052367-05
Lukashevich (PI)
MOP/LAS chimeric vaccine against Lassa Fever, 2003-2009
NIH/NIAID: 5R01AI068961-04
Lukashevich (PI)
Recombinant Yellow Fever 17D-Lassa Vaccine, 2007-2010
NIH/NIAID: 1R21 AI074790-01A2
Salvato/Lukashevich
Lassa Vaccine in primates with AIDS, 2008-2010
Publications
Bredenbeek PJ, Molenkamp R, Spaan WJM, Deubel V, Marianneau P, Salvato MS, Moshkoff D, Zapata J, Tikhonov I, Patterson J, Carrion R, Ticer A, Brasky K, Lukashevich IS. (2006). A Recombinant Yellow Fever 17D Vaccine Expressing Lassa Virus Glycoproteins. Virology, 345: 299-304.
Moshkoff D, Salvato M, Lukashevich IS. (2006). Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes, 34:169-176.
Carrion R, Jr., Patterson JL, Johnson C, Gonzales M, Moreira CR, Ticer A, Brasky K, Hubbard GB, Moshkoff D, Zapata J, Salvato MS, Lukashevich IS. (2007). A ML29 reassortant virus protects guinea pigs against a distantly-related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine, 25:4093-4102.
Carrion, Jr., Brasky K, Mansfield K, Johnson C, Gonzales M, Ticer A, Lukashevich I, Tardif S, Patterson JL. (2007). Lassa Virus Infection in Experimentally Infected Marmosets: Liver Pathology and Immunophenotypic Alterations in Target Tissues. J. Virol., 81: 6482-6490.
Djavani MM, Crasta O, Zapata JC, Fey Z, Folkers O, Sobral B, Swindells M, Bryant J, Davis H, Pauza CD, Lukashevich IS, Hammamieh R, Jett M, Salvato MS. (2007). Early blood profiles of virus infection in a monkey model for Lassa fever. J. Virol., 81:7960-7973.
Yamayoshi S, Noda T, Ebihara H, Goto H, Morikawa Y, Lukashevich IS, Neumann G, Feldmann F, Kawaoka Y. (2008). Ebola Virus Matrix VP40 Protein Uses the COPII Transport System for Its Intracellular Transport. Cell Host Microbe, 3(3):168-177.
Lukashevich IS, Carrion R, Jr, Salvato MS, Mansfield M, Brasky B, Zapata J et al. (2008). Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa Fever in small non-human primates. Vaccine, 26:5246-5254.
Faculty members:
Click here to update your contact information and create a profile.
|